​

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRTX Stock Forecast

Vertex Pharmaceuticals (VRTX) stock forecast, based on 56 Wall Street analysts, predicts a 12-month average price target of $552.80, with a high of $616.00 and a low of $436.00. This represents a 22.01% increase from the last price of $453.06.

$350 $410 $470 $530 $590 $650 High: $616 Avg: $552.8 Low: $436 Last Closed Price: $453.06

VRTX Stock Rating

Vertex Pharmaceuticals stock's rating consensus is Buy, based on 56 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 47 Buy (83.93%), 9 Hold (16.07%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 56 0 9 47 Strong Sell Sell Hold Buy Strong Buy

VRTX Price Target Upside V Benchmarks

TypeNameUpside
StockVertex Pharmaceuticals22.01%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts61341
Avg Price Target$536.50$551.92$521.46
Last Closing Price$453.06$453.06$453.06
Upside/Downside18.42%21.82%15.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 2652151-32
Apr, 2652241133
Mar, 2642151132
Feb, 2641861130
Jan, 26217101131
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 06, 2026Barclays$615.00$424.3644.92%35.74%
May 05, 2026Morgan Stanley$616.00$417.7247.47%35.96%
May 05, 2026Brian AbrahamsRBC Capital$543.00$429.8526.32%19.85%
May 05, 2026Bernstein$572.00$429.8533.07%26.25%
May 05, 2026Canaccord Genuity$436.00$429.851.43%-3.77%
Apr 30, 2026Canaccord Genuity$437.00$423.243.25%-3.54%
Apr 10, 2026Morgan Stanley$612.00$436.8940.08%35.08%
Mar 10, 2026Joon LeeTruist Financial$525.00$499.145.18%15.88%
Mar 10, 2026Akash TewariJefferies$580.00$496.5016.82%28.02%
Mar 02, 2026Evan David SeigermanBMO Capital$600.00$487.5723.06%32.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 06, 2026BarclaysOverweightOverweighthold
May 05, 2026Morgan StanleyOverweightOverweighthold
May 05, 2026RBC CapitalOutperformOutperformhold
Apr 10, 2026Morgan StanleyOverweightOverweighthold
Mar 10, 2026BernsteinOutperformOutperformhold
Mar 10, 2026JefferiesHoldBuyinitialise
Mar 02, 2026BMO CapitalOutperformOutperformhold
Feb 17, 2026BarclaysOverweightOverweighthold
Feb 13, 2026Morgan StanleyOverweightOverweighthold
Feb 13, 2026ScotiabankOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $2 $9 $16 $23 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.09$12.97$14.05$-2.08$15.46---
Avg Forecast$12.96$14.60$15.03$0.48$18.47$20.49$22.97$25.82
High Forecast$14.54$16.11$15.40$1.12$19.96$25.45$28.82$29.56
Low Forecast$12.26$13.86$14.65$0.06$16.67$17.06$19.12$24.25
Surprise %-29.86%-11.16%-6.52%-533.33%-16.30%---

Revenue Forecast

$7B $9B $11B $13B $15B $17B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.57B$8.93B$9.87B$11.02B$12.00B---
Avg Forecast$7.50B$8.93B$9.86B$10.89B$11.77B$12.86B$13.94B$15.25B
High Forecast$8.21B$9.64B$9.91B$10.97B$13.68B$12.87B$14.04B$16.94B
Low Forecast$7.19B$8.58B$9.79B$10.85B$11.22B$12.85B$13.85B$14.53B
Surprise %0.97%-0.03%0.06%1.17%1.97%---

Net Income Forecast

$-1B $800M $3B $4B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.34B$3.32B$3.62B$-535.60M$3.95B---
Avg Forecast$2.08B$2.40B$3.62B$153.32M$4.77B$4.87B$5.30B$6.73B
High Forecast$2.50B$2.88B$4.34B$291.61M$5.20B$6.63B$7.51B$7.70B
Low Forecast$1.66B$1.92B$2.90B$15.03M$4.34B$4.44B$4.98B$6.32B
Surprise %12.58%38.24%--449.33%-17.14%---

VRTX Forecast FAQ

Is Vertex Pharmaceuticals stock a buy?

Vertex Pharmaceuticals stock has a consensus rating of Buy, based on 56 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 47 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vertex Pharmaceuticals is a favorable investment for most analysts.

What is Vertex Pharmaceuticals's price target?

Vertex Pharmaceuticals's price target, set by 56 Wall Street analysts, averages $552.8 over the next 12 months. The price target range spans from $436 at the low end to $616 at the high end, suggesting a potential 22.01% change from the previous closing price of $453.06.

How does Vertex Pharmaceuticals stock forecast compare to its benchmarks?

Vertex Pharmaceuticals's stock forecast shows a 22.01% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vertex Pharmaceuticals over the past three months?

  • May 2026: 15.62% Strong Buy, 65.62% Buy, 15.62% Hold, 3.12% Sell, 0% Strong Sell.
  • April 2026: 15.15% Strong Buy, 66.67% Buy, 12.12% Hold, 3.03% Sell, 3.03% Strong Sell.
  • March 2026: 12.50% Strong Buy, 65.62% Buy, 15.62% Hold, 3.12% Sell, 3.12% Strong Sell.

What is Vertex Pharmaceuticals’s EPS forecast?

Vertex Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $20.49, marking a 32.54% increase from the reported $15.46 in 2025. Estimates for the following years are $22.97 in 2027, and $25.82 in 2028.

What is Vertex Pharmaceuticals’s revenue forecast?

Vertex Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $12.86B, reflecting a 7.17% increase from the reported $12B in 2025. The forecast for 2027 is $13.94B, and $15.25B for 2028.

What is Vertex Pharmaceuticals’s net income forecast?

Vertex Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $4.87B, representing an 23.31% increase from the reported $3.95B in 2025. Projections indicate $5.3B in 2027, and $6.73B in 2028.